Lipocine Inc. Form 3 August 02, 2013

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

(Last)

ELAN CORP PLC

(First) (Middle)

Statement

(Month/Day/Year)

07/24/2013

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Lipocine Inc. [MBARD]

4. Relationship of Reporting Person(s) to Issuer

Filed(Month/Day/Year)

TREASURY BUILDING, Â LOWER GRAND

CANAL STREET

(Street)

\_X\_ 10% Owner Director

(Check all applicable)

Officer Other (give title below) (specify below) 6. Individual or Joint/Group

5. If Amendment, Date Original

Filing(Check Applicable Line) Form filed by One Reporting

Person

\_X\_ Form filed by More than One

Reporting Person

DUBLIN 2, L2Â 00000

(City) (State)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial

Form: Direct (D) Ownership (Instr. 5)

or Indirect (I)

(Instr. 5)

Common Stock 800,394  $I^{(1)}$ Indirect (1)

Reminder: Report on a separate line for each class of securities beneficially

(Zip)

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

**Expiration Date** 

2. Date Exercisable and 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Derivative Security:

(Instr. 4)

(Month/Day/Year)

Price of Derivative

### Edgar Filing: Lipocine Inc. - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of Shares (I)

(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Othe
ELAN CORP PLC TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2, L2 00000	Â	ÂX	Â	Â
Elan Pharma International LTD TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2, L2 00000	Â	ÂX	Â	(1)
ELAN INTERNATIONAL SERVICES LTD C/O TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2 Â L 2Â 00000	Â	ÂX	Â	Â

# **Signatures**

/s/ William F. Daniel, Executive Vice President and Company Secretary

08/02/2013

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

718,483 shares are directly owned by Elan International Services Limited, an indirect wholly-owned subsidiary of Elan Corporation, plc ("Elan"), and 81,911 shares are directly owned by Elan Pharma International Limited, an indirect wholly-owned subsidiary of Elan. Elan Pharma International Limited may be deemed to be a member of a 13(d) group (with Elan and Elan International Services Limited) constituting a 10% owner.

Â

#### **Remarks:**

Exhibit List: Exhibit 99.1 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2